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Abstract
Infectious Bursal Disease Virus (IBDV) is the etiological agent 
of an immunosuppressive and highly contagious disease that 
affects young birds causing important economic losses in the 
poultry industry. The structural protein VP2 has been used for 
the development of subunit vaccines in a variety of heterologous 
platforms. We have previously demonstrated that plant-derived 
VP2 (pVP2) is able to elicit a neutralizing antibody response in 
chickens when administered intramuscularly (i.m.) in a prime/boost 
scheme. However, administration via injection is impractical and 
carries the risk of needle stick injury or pain. Mucosal vaccination 
is noninvasive and has several advantages over traditional 
systemic vaccines. Taking this into account and the fact that 
natural infections with IBDV occur by the oral route, we decided 
to investigate whether pVP2 was also immunogenic when given 
intranasally (i.n.) or orally to chickens. In addition, we evaluated if 
intramuscular vaccination with VP2 plant extract in a more welfare-
friendly scheme with less injections and without adjuvant was able 
to elicit a protective immune response against IBDV as previously 
seen. We determined that animals inoculated i.m., but not i.n., 
with the experimental vaccine developed high titres of specific 
antibodies, with virus neutralizing activity. Also, bursae of animals 
vaccinated i.m. with pVP2 presented few infiltrating T cells, low viral 
charge and normal morphology. However, chickens that received the 
immunogen via nasal or oral route were not protected after challenge. 
Considering the disadvantages of conventional live-attenuated and 
inactivated vaccines, a plant-based subunit vaccine represents a 
viable alternative in the veterinary field. Once again pVP2 has proven 
to be immunogenic when parentally inoculated. However, further 
investigations need to be done in order to find an alternative route of 
administration which is more practical than the intramuscular injection 
and capable of eliciting a mucosal immune response
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Introduction
Infectious Bursal Disease is an acute, highly contagious, 
immunosuppressive disease that affects young birds causing 
important economic losses in the poultry industry worldwide. Its 
etiological agent is the Infectious Bursal Disease Virus (IBDV), a 
non-enveloped icosahedral bisegmented double-stranded RNA virus, 
member of the Birnaviridae Family [1]. IBDV infects and destroys 
IgMbearing B-lymphocytes in the bursa of Fabricius (BF), which 
results in immunosuppression [2,3] and T cells infiltration into this 
organ [4].
Currently, vaccination with inactivated and live-attenuated 
vaccines induces immunity in the flock against virulent viruses. 
However, conventional vaccines have a number of disadvantages 
because of their viral nature. For instance, live-attenuated vaccines 
can revert to virulence by recombination of RNA segments [5], 
they usually produce a temporary state of immunosuppression in 
young chickens, and they can be inefficient in protecting birds from 
very virulent and variant IBDV strains [6,7]. Moreover, inactivated 
vaccines are costly and lack efficient immunogenicity unless they are 
adjuvated and administered in multiple inoculations, or delivered as 
a booster after priming with a replicating antigen. Thus, there is a 
genuine need to replace conventional virus-based vaccines by new 
ones with higher efficacy and fewer side-effects. The structural protein 
VP2, which contains the major neutralizing epitopes, has been used 
for the development of subunit vaccines in a variety of heterologous 
systems such as recombinant fowlpoxvirus [8], herpesvirus [9-11], 
adenovirus [12,13], baculovirus [14,15], Escherichia coli [16], Pichia 
pastoris [17] and plant virus [18]. In addition, DNA vaccines have 
been obtained [19, 20] and VP2 production and immunogenicity 
have been reported in transgenic Arabidopsis thaliana [21] and rice 
[22].
Since the past two decades plants have been considered a 
promising system to produce subunit vaccines given that they offer 
significant advantages over conventional expression systems, such 
as time and cost efficiency, lower risk of contamination from animal 
pathogens and nearly-unlimited scalability [23]. Furthermore, it is 
well documented that antigens expressed in planta are capable of 
inducing protective response when administered by oral or parenteral 
routes. For these reasons, the technology to produce recombinant 
vaccines in plant cells has evolved from modest proofs of concept to 
viable technologies adopted by some companies [24].
In a previous study, we investigated the expression, 
immunogenicity and protective efficacy of a plant-based VP2 (pVP2) 
vaccine against IBDV [25]. We determined that agroinfiltration 
of N.benthamiana leaves allowed the production of VP2 and that 
chickens intramuscularly immunized in a 3 doses scheme with 
adjuvated concentrated plant extract developed a specific humoral 
response with viral neutralizing capacity. We also demonstrated 
that pVP2 had the ability to prevent T-cell infiltration into the bursa 
as a parameter of protection against an infectious virus. However, 
administration via injection is impractical and carries the risk of needle 
stick injury or pain. Mucosal vaccination is non-invasive and does 
not involve the use of needles. Moreover, mucosal administration of 
vaccines is relatively easy and does not require specialized personnel. 
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groups (4, 5 and 6) received plant extract containing GFP (pGFP) as a 
non-related antigen by i.m., i.n. and oral route respectively. Fourteen 
days post first immunization (dpi) chickens were boosted following 
the same scheme. All animals were bled by the wing vein every eleven 
days. Three weeks after boost (35 dpi), 6 out of 9 chickens per group 
were challenged by oral inoculation with 500 µl of the intermediate 
IBDV strain LZD (6934 TCID50/ml) purchased from Laboratorios 
Inmuner (Entre Ríos, Argentina). 3 chickens of each group were left 
unchallenged. Five days later (40 dpi) animals were euthanized and 
bursae were removed.
Antibody response against IBDV
Sera were evaluated for the presence of specific antibodies against 
IBDV with a commercial kit (cat No. 99-09260, IDEXX Laboratories, 
Inc., USA). Titers were calculated following the manufacturer’s 
instructions. Values above 396 were considered positive.
Seroneutralization assay
Seroneutralization assay was performed as previously described 
[25]. Briefly, sera were inactivated for 30 min at 56 °C, serially diluted 
twofold in culture medium and incubated with 100 TCID50 of IBDV 
strain LZD for 1 h at 37 °C in 96-well plates. Subsequently, 100 µl 
of a cell suspension of 1.5 × 106 chicken embryo fibroblasts (CEFs)/
ml were added to each well. Cells were cultured at 37°C, % CO2 for 
4 days, when cytopathic effect was observed. Neutralizing antibody 
titers were calculated as the inverse of the last dilution showing no 
cytopathic effect.
Lymphocyte isolation and flow cytometry analysis
Bursal samples were pooled (in pairs in the case of challenged 
animals or in threes for unchallenged animals) and used to study 
mononuclear cell populations by flow cytometry as described [29]. 
Briefly, bursae were mechanically disrupted in RPMI 1640 and cellular 
suspensions were passed through a 40 μm mesh (Cell Strainer, BD). 
Mononuclear cells were isolated by centrifugation over Histopaque 
density gradient. 1×106 cells per well were seeded on 96-well plates 
and stained with different combinations of antibodies. Monoclonal 
antibodies (mAbs) (CD3-SPRD, CD4-PE, CD8α-FITC, CD8β-PE) 
were purchased from Southern Biotech. (Birmingham, AL). Cell 
suspensions were analyzed with a FACS Calibur flow cytometer (BD 
Biosciences, San Jose, CA) and CellQuest software. The lymphocyte 
gate was defined by the forward/side scatter characteristics of the cells 
and 50,000 events were analyzed for each sample.
IBDV isolation from bursa
Pieces of bursae were mechanically disrupted in one volume of 
PBS and 3 frost/thaw cycles were performed. Homogenates were ten-
fold serially diluted in culture medium (199 1X supplemented with 
triptose phosphate broth, HEPES 25 mM, pH 7) and used to infect 
CEFs monolayers seeded in 96-well plates. After adsorption for 1 hour 
at 37°C, virus was removed and fresh medium (199 1X supplemented 
with triptose phosphate broth, HEPES, 1.5% Fetal Bovine Serum and 
antibiotic/antimycotics) was added. After 4 days at 37°C, 5% CO2, the 
presence of cytopathic effect was evaluated in each well. Viral titer 
was expressed as TCID50/ml using the Reed and Muench method.
Histopathological observation of bursa
Bursal samples were placed in 10% neutral buffered formalin 
and paraffin embedded. Sections of the paraffin embedded BF were 
stained with haematoxylin and eosin following standard histological 
Reduced adverse effects and the potential for frequent boosting may 
also represent further advantages over injectable vaccines [26].
 Taking this into account and the fact that simultaneous 
stimulation of mucosal IgA and systemic IgG responses would be 
desirable for an anti IBDV vaccine since natural infections occur 
by the oral route [27], we decided to investigate whether pVP2 was 
also immunogenic when given intranasally or orally to chickens. 
Additionally, we evaluated if intramuscular vaccination with VP2 
plant extract in a more welfare-friendly prime/boost scheme with 
less injections and without adjuvant was able to elicit a protective 
immune response against IBDV as previously seen.
Materials and Methods
Genetic engineering of the expression vector 
Construction of the plant expression vector containing VP2 was 
described previously [25]. Briefly, the coding region of the mature 
VP2 (1323 bp) was amplified from the Argentinian field isolate LD-
04 of IBDV kindly provided by Dr. Delamer (Empresa Delamer 
S.R.L., Argentina), cloned into the commercial 1.1tag vector and 
subcloned into the binary vector pBINPLUS (IMPACTVECTORTM, 
Wageningen UR, Netherlands). The resulting expression vector was 
introduced into A. tumefaciens strain GV3101 by electroporation.
Transient expression of VP2
Transient expression was performed by infiltrating Nicotiana 
benthamiana leaves with a suspension of recombinant bacteria 
as previously described [28]. A construction harboring the green 
fluorescent protein (GFP) was added as a negative control. The 
infiltrated leaves were harvested 4 days postinoculation and grounded 
in liquid nitrogen. Subsequently, 3 volumes of chilled extraction 
buffer (100 mM Sodium acetate pH 4, 1 mM EDTA, 5% glycerol, 0.5% 
NP40 and protease inhibitor cocktail (Roche, Mannheim, Germany) ) 
were added. After 30 min incubation on ice, samples were centrifuged 
for 30 min at 20000×g and filtered through gauze. Samples pH were 
raised to 7 for animal inoculation and kept at −80°C until use.
Detection and quantification of the recombinant protein
 VP2 expression was analyzed by Western blot assays. Briefly, 
extracted proteins were separated in 12% SDS-PAGE and blotted onto 
nitrocellulose membrane. Proteins were identified using an antiVP2 
rabbit polyclonal antibody produced in our laboratory. For protein 
quantification, we performed a standard curve of bovine serum 
albumin (BSA). BSA and samples were subjected to SDS-PAGE and 
VP2 amounts were estimated after Coomassie Brilliant Blue staining.
Animals
Embryonated eggs laid by specific pathogen free White Leghorn 
hens were purchased from Instituto Rosenbusch S.A. (CABA, 
Argentina) and hatched in an automatic incubator (Yonar, CABA, 
Argentina). Chickens were kept in individual cages with food and 
water ad libitum. All procedures were approved by the Institutional 
Committee for the Care and Use of Experimental Animals (CICUAE–
CICVyA–INTA).
Immunization scheme and challenge
Nine chickens of 21 days of age were randomly assigned to 
each group. Animals received 250 µl of a plant extract containing 
approximately 7.5 µg of VP2 via intramuscular (i.m.) (group 1), 
intranasal (i.n.) (group 2) or oral (group 3) administration. Control 
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procedures. The stained sections were microscopically examined for 
the presence of bursal lesions by light microscopy.
Results
Immunogenicity of plant-derived VP2 in SPF chickens
Before performing chicken experiments, expression of 
recombinant VP2 in plant extracts was confirmed by Western blot. 
As shown in Figure 1 a specific band corresponding to the mature 
VP2 was observed at the expected size. The estimated concentration 
of VP2 antigen in the plant extract was approximately 30 ng/µl.
To evaluate the immunogenicity of plant-derived VP2 by different 
routes of administration, chickens were inoculated intramuscularly, 
intranasally or orally with 250 μl of plant extract containing 7.5 μg of 
recombinant VP2 in a prime/boost scheme. Sera were analyzed for 
the presence of specific antibodies against IBDV using a commercial 
ELISA assay. Figure 2 shows that all animals i.m. injected with pVP2 
(group 1, Figure 2B) mounted a humoral response detected at 21 
dpi (one week after boost), reaching its highest titers by the end 
of the experiment. However, animals i.n. (group 2) or orally (group 
3) vaccinated with the same immunogen failed to generate specific 
antibodies against IBDV. As expected, control groups that received plant 
extract containing GFP (groups 4, 5 and 6) had undetectable levels of 
antibodies independently of the inoculation route (Figure 2A).
Furthermore, antibodies against IBDV present in group 1 
exhibited virus neutralizing ability. Figure 3 shows the neutralizing 
titers expressed as the log10 of the inverse of the last dilution without 
cytopathic effect of samples corresponding to 32 dpi (18 days after 
boost). Sera from other groups were not evaluated given that specific 
antibodies against IBDV were not detected.These results indicate 
that VP2 produced in plants is able to elicit an appropriate humoral 
response in chickens when administered intramuscularly but not 
intranasally or orally.
Evaluation of cellular populations by flow cytometry
After infection, IBDV replication in the bursa involves an 
infiltration of T cells into this organ [4]. Hence, we investigated the 
frequency of T cells in the bursa of vaccinated animals after challenge 
with a high dose of an intermediate IBDV strain to determine if the 
inoculation of pVP2 through different routes was able to elicit a 
protective immune response. Results are shown in Figure 4 and they 
are expressed as the fold increase of each sample normalized with the 
mean value of unchallenged chickens. Animals i.m. inoculated with 
pVP2 (group 1) showed less T lymphocyte infiltration (from a 1.3 to 
a 2.6 fold increase) than chickens from group 2 and 3 vaccinated with 
the same immunogen by the intranasal and oral route respectively, 
in which fold increase varied from 6.7 to 42.8 times. Within the 
infiltrating CD3+ lymphocytes, most of them corresponded to 
CD8αβ+ cells. As expected, pGFP groups showed elevated numbers of 
infiltrating T lymphocytes.
Morphological and histological observation of bursa
 Bursae from animals immunized i.m. with pVP2 had no gross 
lesions and exhibited a normal morphology. However, bursae from 
chickens in groups 2 and 3 displayed a yellowish appearance and 
haemorrhages, typical signs of IBDV infection, as seen in pGFP 
groups (data not shown). Regarding microscopical observation, 
bursae from group 1 were, histopathologically comparable to those 
from animals unchallenged, although some of them contained few 
apoptotic lymphocytes. On the contrary, the rest of the animals had 
damaged bursae with different degrees of lymphoid atrophy, necrosis 
and apoptosis. Edema, congestion and small haemorrhages, together 
with lymphocyte and heterophile infiltration were also observed in 
these animals (Figure 5).
Viral isolation
Finally, to evaluate the protective effect of the recombinant 
vaccine by different routes of inoculation, viral isolation assays from 
bursae after challenge were performed. Results are shown in Table 
1. As expected, IBDV was not detected in unchallenged chickens 
while high viral titers were observed in bursae from control animals 
inoculated with pGFP (groups 4, 5 and 6). Animals in group 1 which 
were i.m. immunized with pVP2 revealed a notable decrease in the 
viral titer recovered from bursa. In four out of six chickens, IBDV was 
not detected while the other two animals showed a reduction in the 
viral titer of approximately 105 times. However, chickens i.n or orally 
inoculated with pVP2 (groups 2 and 3 respectively) had viral titers 
undistinguishable from control groups.
Taken together, the results evidence that mucosal vaccination 
with pVP2, in the conditions tested, is unable to generate a protective 
response that prevents IBDV entrance or replication in bursa.
Discussion
In this study, we investigated if the inoculation of pVP2 through 
different routes was able to elicit a protective immune response 
against IBDV. We have previously demonstrated that chickens 
intramuscularly immunized with adjuvated concentrated plant extract 
at 0, 22 and 35 dpi developed a specific humoral response with viral 
neutralizing ability that prevented totally or partially the entrance of 
IBDV, reducing T-cell infiltration into the bursa [25]. Here we showed 
that two i.m. injections were enough to elicit a protective immune 
response with high titers of specific and neutralizing antibodies 
(Figures 2 and 3). In addition, we observed that this immunization 
scheme prevented the entrance or replication of IBDV in bursa as 
evidenced by the low viral titers in this organ (Table 1), as well as 
T-cell infiltration and bursal damage (Figures 4 and 5). Furthermore, 
Figure 1: VP2 transient expression in Nicotiana benthamiana plants. 
Proteins were separated on a 12% SDS-PAGE and recombinant VP2 
was identified using an anti-VP2 antiserum (lane 1).Control plant extract 
containing GFP was loaded in lane 2. MM: molecular marker (Page Ruler 
Plus Prestained Protein Ladder, Thermo Scientific).
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Figure 2: Evaluation of plasma samples by ELISA: Animals were 
vaccinated on 0 and 14 dpi with plant extracts containing VP2 by i.m. 
(group 1), i.n. (group 2) or oral (group 3) route. Control groups (4, 5 and 6) 
were inoculated with plant extract containing GFP using the same routes 
respectively, A. Anti-IBDV titers represented as the mean ± S.D. for each 
group and date of the time course. Titers above the cutoff point (396) were 
considered positive. B. Individual titers for chickens in group 1.
adjuvant was not needed in order to achieve immunoprotection 
against IBDV. Plant extracts, including Nicothiana benthamiana’s, 
have been reported to modulate the monocyte differentiation in 
dendritic cells and their maturation, although the chemical nature of 
the compounds responsible for their immunomodulatory properties 
has yet to be determined [30-32]. Lack of adjuvants, which tend to 
cause inflammation and ulceration at the site of injection, as well as few 
inoculations, are desirable characteristics for a vaccine since they imply 
less distress in the animals. Therefore, we consider that our plant-based 
VP2 could be a promising alternative to traditional inactivated vaccines 
which are more expensive to produce and poorly immunogenic unless 
they are adjuvated and administered in multiple inoculations.
As regarding mucosal vaccination with pVP2, results were less 
encouraging. Neither intranasal nor oral vaccinations were able 
to produce an effective immune response in chickens. Specific 
antibodies were not detected and chickens were not protected 
from IBDV challenge. Their bursa had elevated viral titers and high 
T-lymphocyte infiltration which caused important bursal damage.
In all, these animals were undistinguishable from those 
inoculated with GFP.VP2 has been assessed as an immunogen 
by the oral route in previous investigations. Five oral doses at 3 
days intervals of soluble VP2 expressed in A. thaliana (11.44 μg of 
VP2 in total) induced an antibody response and 80% of protection 
against challenge [21]. Furthermore, fasted chickens fed with rice 
seeds expressing VP2 (between 5 and 10 mg) produced neutralizing 
antibodies against IBDV and were protected (83.33%) against 
challenge [22]. Oral immunization using different strains of yeasts 
containing VP2 were also investigated with diverse outcomes. Only 
10% of chickens administered Kluyveromyces lactis expressing VP2 
(1-3 mg of recombinant protein in total) in a 2/2/2 scheme (two 
weeks feeding, two weeks break, two weeks feeding) were protected 
from depletion of B lymphocytes in the bursal follicles after challenge 
although no mortality or clinical signs were observed in none of these 
animals [33]. On the contrary, 4 doses of orally administered Pichia 
pastoris producing VP2, containing 400 µg or 4 mg of viral protein, 
induced a protective immune response against IBDV in chickens 
which increased survival rates to 60 % compared to 40% in the control 
groups [34]. These studies demonstrate that VP2 is resistant to gut 
degradation, based on the fact that it invoked an immune response. 
However, the amounts of antigen used in these reports were much 
higher than the concentration evaluated in our study, so we do not 
discard the possibility that larger mass of pVP2 or addition of an oral 
adjuvant [27,34-36] could be needed to elicit an immune response by 
the oral route. Protein concentration in our plant extract has always 
been a limiting factor; therefore we are looking into ways to improve 
VP2 expression and/or recovery.
Intranasal or oculonasal immunization in chickens is mostly 
used with live attenuated or vector vaccines [37-39], but there are 
few studies about protein subunit or inactivated vaccines delivered 
by this route. Intranasal administration of recombinant outer 
membrane protein H (rOmpH) expressed in bacteria has been 
evaluated as a potential fowl cholera vaccine candidate for chickens 
[40]. One inoculation of 50 µg of rOmpH adjuvated with Escherichia 
coli enterotoxin B or CpG oligodeoxynucleotides mounted IgY and 
IgA antibody responses and conferred 70% and 90% protection 
Figure 3: Neutralizing antibody response of animals vaccinated i.m. 
with VP2 at 32 dpi. Titers are expressed as the log10 of the inverse of the 
last dilution that prevented the appearance of cytopathic effect for individual 
samples. Negative control: serum from an unvaccinated animal, Positive 
control: serum from an animal inoculated with a commercial live attenuated 
vaccine.
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Sample TCID50 / ml
1.1 Neg
1.2 Neg
1.3 Neg
1.4 1.86 × 104
1.5 Neg
1.6 1.26 × 104
2.1 4.00 × 107
2.2 2.7 × 107
2.3 > 1.26 × 109
2.4 8.6 × 108
2.5 > 1.26 × 109
2.6 8.6 × 108
3.1 > 1.26 × 109
3.2 1.26 × 108
3.3 6.80 × 108
3.4 > 1.26 × 109
3.5 8.60 × 108
3.6 4.00 × 108
4.1 1.46 × 108
4.2 > 1.26 × 109
4.3 > 1.26 × 109
4.4 > 1.26 × 109
4.5 4.00 × 106
4.6 7.10 × 108
5.1 > 1.26 × 109
5.2 > 1.26 × 109
5.3 > 1.26 × 109
5.4 1.26 × 108
5.5 1.86 × 108
5.6 > 1.26 × 109
6.1 8.60 × 108
6.2 4.00 × 108
6.3 1.26 × 107
6.4 > 1.26 × 109
6.5 1.86 × 108
6.6 > 1.26 × 109
Table 1: Viral isolation from bursa after challenge:  Pieces of bursa from group 
1 (i.m. pVP2), group 2 (i.n. pVP2), group 3 (oral pVP2), group 4 (i.m. pGFP), group 
5 (i.n. pGFP) and group 6 (oral pGFP) were mechanically disrupted in PBS and 
3 frost/thaw cycles were performed. Homogenates were ten-fold serially diluted 
and the dilutions were used to infect monolayers of chicken embryo fibroblasts 
seeded in 96-well plates. After 4 days at 37 °C, the presence of cytophatic effect 
was evaluated in each well. Viral titer was e×pressed as TCID50/ml, using the 
Reed and Muench method. Neg: negative results correspond to a viral titer lower 
than 1.26 × 103 TCID50/ml.
Figure 4: Evaluation of cellular populations in bursa by flow 
cytometry: Bursae from challenged animals in groups 1 (i.m. pVP2), 
2 (i.n. pVP2), 3 (oral pVP2), 4 (i.m. pGFP), 5 (i.n. pGFP) and 6 (oral 
pGFP) were pooled in pairs and chicken leukocytes were isolated, 
stained with different combinations of antibodies and analyzed by 
flow cytometry. Lymphocyte population was gated according to their 
size and complexity. Results are expressed as the fold increase 
of each sample normalized with the mean values of unchallenged 
chickens.
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Figure 5: Histopathological observation of bursa. Bursal samples from group 1 (i.m. pVP2, A), group 2 (i.n. pVP2, B), group 3 (oral pVP2, C), group 4 (i.m. 
pGFP, D), group 5 (i.n. pGFP, E) andgroup 6 (oral pGFP, F) were paraffin embedded and stained with haematoxylin and eosin. Bursae from group 1 were 
histopathologically normal although some of them contained few apoptotic lymphocytes. The rest of the animals had damaged bursae with different degrees of 
lymphoid atrophy, necrosis, apoptosis, edema,  small haemorrhages and lymphocyte and heterophile infiltration.
respectively. Another study demonstrated that i.n. administration 
of inactivated Newcastle disease virus (NDV) induced local humoral 
responses and protected birds from lethal challenge with virulent 
virus. Addition of cholera toxin B subunit to inactivated vaccine 
increased antibodies titers and protection rates [41]. We believe 
that supplementation of our recombinant vaccine formulation with 
an appropriate mucosal adjuvant could be necessary to achieve the 
desire protective state against IBDV since immunomodulators are 
often needed for strong mucosal immune responses [42].
 Taken into account the disadvantages of the commercial live-
attenuated and inactivated vaccines, a plant-based subunit vaccine 
represents a viable alternative in the veterinary field [43,44]. Our 
transiently expressed VP2 conserves antigenic determinants of 
the wild type protein and has proven to be immunogenic when 
parentally inoculated. However, further investigations need to be 
done to improve the pVP2 formulation in order to be able to use a 
more practical route of administration capable of eliciting a mucosal 
immune response.
 In conclusion, our study reveals that an intramuscular vaccine 
based on plant material expressing the main immunodominant 
antigen of IBDV can be a welfare-friendly and desirable vaccine to 
apply in the poultry industry.
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